- WHI-P180
-
- $42.00
-
2026-07-27
- CAS:211555-08-7
- Purity: 99.21%
- Supply Ability: 10g
|
| | Phenol, 3-[(6,7-diMethoxy-4-quinazolinyl)aMino]- Basic information |
| Product Name: | Phenol, 3-[(6,7-diMethoxy-4-quinazolinyl)aMino]- | | Synonyms: | Phenol, 3-[(6,7-diMethoxy-4-quinazolinyl)aMino]-;3-[(6,7-Dimethoxy-4-quinazolinyl)amino]phenol;Janex 3;3-(6,7-dimethoxyquinazolin-4-ylamino)phenol;3-[(6,7-dimethoxyquinazolin-4-yl)amino]phenol (Related Reference);WHI P180;JANEX3;WHIP180;JANEX-3;WHI-P180(Janex 3);WHI-P180, >98% | | CAS: | 211555-08-7 | | MF: | C16H15N3O3 | | MW: | 297.31 | | EINECS: | | | Product Categories: | Inhibitors | | Mol File: | 211555-08-7.mol | ![Phenol, 3-[(6,7-diMethoxy-4-quinazolinyl)aMino]- Structure](CAS/20150408/GIF/211555-08-7.gif) |
| | Phenol, 3-[(6,7-diMethoxy-4-quinazolinyl)aMino]- Chemical Properties |
| Boiling point | 476.5±40.0 °C(Predicted) | | density | 1.336±0.06 g/cm3(Predicted) | | storage temp. | 2-8°C(protect from light) | | solubility | DMSO : 25 mg/mL (84.09 mM; Need ultrasonic)H2O : < 0.1 mg/mL (insoluble) | | form | Powder | | pka | 9.58±0.10(Predicted) | | color | White to off-white | | InChI | 1S/C16H15N3O3/c1-21-14-7-12-13(8-15(14)22-2)17-9-18-16(12)19-10-4-3-5-11(20)6-10/h3-9,20H,1-2H3,(H,17,18,19) | | InChIKey | BNDYIYYKEIXHNK-UHFFFAOYSA-N | | SMILES | N(c3cc(ccc3)O)c1ncnc2c1cc(c(c2)OC)OC |
| WGK Germany | WGK 1 | | Storage Class | 11 - Combustible Solids |
| | Phenol, 3-[(6,7-diMethoxy-4-quinazolinyl)aMino]- Usage And Synthesis |
| Uses | WHI-P180 (Janex 3) is a multi-kinase inhibitor; inhibits RET, KDR and EGFR with IC50s of 5 nM, 66 nM and 4 μM, respectively. | | Biological Activity | WHI-P180 is an inhibitor of multiple kinases with IC50 values of 4.5 nM and 66 nM for RET (c-RET) and KDR, respectively. | | in vivo | WHI-P180 is also an active inhibitor of IgE-mediated mast cell responses. The elimination half-life of WHI-P180 in CD-1 mice (BALB/c mice) following iv, ip, or po administration is less than 10 min. Systemic clearance of WHI-P180 is 6742 mL/h/kg in CD-I mice and 8188 mL/h/kg in BALB/c mice. Notably, WHI-P180, when administered in two consecutive nontoxic ip bolus doses of 25 mg/kg, inhibits IgE/antigen-induced vascular hyperpermeability in a well-characterized murine model of passive cutaneous anaphylaxis. | | target | | Target | Value | RET
(Cell-free assay) | 4.5 nM | KDR
(Cell-free assay) | 66 nM |
| | IC 50 | EGFR: 4 μM (IC50); KDR: 66 nM (IC50); RET: 5 nM (IC50) | | References | [1] Newton R, et al. The discovery of 2-substituted phenol quinazolines as potent RET kinase inhibitors with improved KDR selectivity. Eur J Med Chem. 2016 Apr 13;112:20-32. DOI:10.1016/j.ejmech.2016.01.039
[2] Ghosh S, et al. 4-[3-Bromo-4-hydroxyphenyl)amino]-6,7-dimethoxyquinazolin-1-ium chloride methanol solvateand 4-[(3-hydroxyphenyl)amino]-6,7-dimethoxy-1-quinazolinium chloride. Acta Crystallogr C. 2001 Jan;57(Pt 1):76-8. DOI:10.1107/s0108270100013561
[3] Chen CL, et al. Pharmacokinetics and biologic activity of the novel mast cell inhibitor, 4-(3-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline in mice. Pharm Res. 1999 Jan;16(1):117-22. DOI:10.1023/a:1018835232027 |
| | Phenol, 3-[(6,7-diMethoxy-4-quinazolinyl)aMino]- Preparation Products And Raw materials |
|